International Trade Bulletin - Volume 1, Issue 8
Client Alert | 1 min read | 06.26.06
Inside this issue:
- EUROPE IN THE SPOTLIGHT
- CHINA IN THE SPOTLIGHT
- RULES OF ORIGIN: “Made in USA” Marking Update
- ANTI-DUMPING IN THE U.S.: The U.S. Department of Commerce formulates comments submitted in response to the U.S.-adverse WTO Appellate Body Report in United States – Zeroing
- FCPA: U.S. Business Optimism Tempered by Corruption in Southeast Asia
- U.S. SANCTIONS
- INTERNATIONAL IP PROTECTION: Supreme Court Decision Likely to Generate More Intellectual Property Import Protection (Section 337) Cases
- MARKET ACCESS: Korea-U.S. FTA Negotiators Set a Fast Pace in First Round of Negotiations
Contacts
Insights
Client Alert | 2 min read | 09.18.25
On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”
Client Alert | 3 min read | 09.17.25
Client Alert | 4 min read | 09.17.25
Client Alert | 5 min read | 09.16.25
Bucking the Odds: Why Technology Companies Should Embrace Software Patents Today
